Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment.

Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

Donisi, C, Pretta, A, Pusceddu, V, Ziranu, P, Lai, E, Puzzoni, M, Mariani, S, Massa, E, Madeddu, C and Scartozzi, M (2024) ...

Prostate cancer and other cancers characterized by “cold” tumors could become more responsive to checkpoint blockade if UBA1 is inhibited.

Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...

Cancer metabolism is a critical area of research, central to understanding how malignant tumors manipulate metabolic pathways to support their growth and survival. These alterations not only fuel ...

University of Michigan researchers identified UBA1 as a key player in immunotherapy resistance. Inhibiting UBA1 boosts T-cell ...

In recent decades, immunotherapy has transformed cancer treatment, offering effective options for diseases once considered ...

The groundbreaking results of the OVATION 2 Study demonstrated a substantial 35% improvement in overall survival, equating to ...

Aptevo Therapeutics (APVO) provided additional details about its oncology pipeline which is poised to potentially address some of the most ...